Roughly half of the bolus of patients we’re talking about already took interferon and ribavirin in the first-line setting; the overwhelming majority (>=75%) of these patients ought to be able to take interferon/ribavirin with Telaprevir or Boceprevir in the second-line setting.
The other half of the bolus of patients we’re talking about consists of those who have never been treated. Unless these patients have a genetic variant known to cause a poor response to interferon/ribavirin, they too ought to be able to take a regimen of interferon/ribavirin with Telaprevir or Boceprevir.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.